[Comparative study of the antigenic activity and allergic transformation of the body in human revaccination with different doses of a chemical brucellosis vaccine].

The study of different doses of chemical brucellosis vaccine (0.5 mg, 0.75 mg and 1 mg), used for the booster immunization of persons who had received primary immunization with chemical and live brucellosis vaccines, revealed that the characteristics of its antigenic potency were somewhat higher after primary immunization with the live vaccine.

[Comparative study of the safety and reactogenicity of different doses of brucellosis chemical vaccine in human revaccination].

The period of 11-12 months has been found to be the optimal interval, among other experimentally tested periods of time, between primary immunization and booster immunization with chemical brucellosis vaccine. The safety and low reactogenicity of different doses (1 mg, 0.75 mg and 0.

[Use of a Brucella protein-polysaccharide antigen for the allergen diagnosis of brucellosis].

The experimental and clinical study of the allergen diagnostic properties of new Brucella protein-polysaccharide antigen in comparison with brucellin has been made in the leukocyte migration inhibition test, and its working doses have been determined. The results thus obtained suggest that Brucella protein-polysaccharide antigen has considerable diagnostic advantages over commercial brucellin, which presents vast possibilities of using this antigen for the allergen diagnosis of brucellosis in the leukocyte migration inhibition test.